Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals LtdfiledCriticalActelion Pharmaceuticals Ltd
Priority claimed from PCT/IB2013/059233external-prioritypatent/WO2014057435A1/en
Publication of MA38075A1publicationCriticalpatent/MA38075A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne des dérivés [ortho bi-(hétéro-)aryl]-[2-(méta bi-(hétéro-)aryl)-pyrrolidin-1-yl]- méthanone de la formule (i) dans laquelle r, et les cycles a1a2 et a3 sont tels que définis dans la description, leurs sels pharmaceutiquement acceptables, leur préparation, des compositions pharmaceutiques contenant au moins un composé de la formule (i), et leur utilisation comme médicaments, en particulier comme antagonistes des récepteurs de l'oréxine.The present invention relates to [ortho-bis (hetero) aryl] - [2- (meta-b (hetero) aryl) -pyrrolidin-1-yl] -methanone derivatives of the formula (i) wherein r, and the rings a1a2 and a3 are as defined in the description, their pharmaceutically acceptable salts, their preparation, pharmaceutical compositions containing at least one compound of the formula (i), and their use as medicaments, in particular as antagonists of the 'orexin.
MA38075A2012-10-102013-10-09
Orexin receptor antagonists, which are [ortho bi (hetero) aryl] - [2- (meta-bi (hetero) aryl) -pyrrolidin-1-yl] -methanone derivatives
MA38075A1
(en)
7-Benzyl-4- (4- (trifluoromethyl) benzyl) -1,2,6,7,8,9-hexahydroimidazo [1,2-a] pyrido [3,4-e] pyrimidin-5 (4h) - one, its salts and their use in therapy